What are the common side effects of Platinib (Pujihua) and how to deal with them scientifically?

Pralsetinib (Pralsetinib) is an oral targeted drug mainly used to treat RET fusion-positive non-small cell lung cancer and certain RET mutation-related thyroid cancers. As a RETkinase inhibitor, platinib can effectively block abnormal signaling pathways and inhibit tumor cell proliferation and metastasis. However, like other targeted drugs, platinib may also cause certain adverse reactions while exerting its efficacy. Clinical data shows that common side effects mainly involve the blood system, digestive system, liver function, and mild to moderate systemic reactions.

In terms of hematology, the most common side effects of platinib include anemia, thrombocytopenia, and neutropenia. Patients may experience symptoms such as fatigue, paleness, easy bleeding, or susceptibility to infection. In response to these situations, clinical practice usually recommends regular blood routine monitoring before treatment and during medication. Once a significant decrease in platelets or neutrophils is found, appropriate intervention should be taken according to the guidance of the doctor, such as temporarily stopping the drug, reducing the dose, or using erythropoiesis-stimulating agents and growth factors as an adjuvant to maintain the stability of blood indicators while avoiding aggravation of the risk of infection and bleeding.

Digestive system side effects are one of the common adverse reactions of platinib, mainly showing nausea, vomiting, diarrhea or loss of appetite. Patients with mild symptoms can be relieved by adjusting their diet, eating small and frequent meals, and adequate hydration; for moderate to severe symptoms, doctors may use antiemetics, antidiarrheals, or electrolyte supplements according to the situation. In addition, platinib sometimes causes oral mucositis or mild liver function abnormalities, and liver function indicators, such as transaminase and bilirubin levels, need to be monitored regularly during treatment. Once obvious liver function abnormalities occur, the drug should be stopped or the dose should be reduced promptly, and liver protection treatment should be taken under the guidance of a doctor.

Systemic symptoms such as fatigue, mild edema, rash, or muscle pain are also common side effects of platinib. In the face of fatigue and muscle soreness, patients can make appropriate light exercise or rest adjustments while maintaining a regular schedule and balanced nutrition. Skin rashes can be controlled with topical or oral anti-allergic drugs under the guidance of a doctor. In addition, a small number of patients may experience increased blood pressure, abnormal heart rhythm or pulmonary symptoms during medication. Therefore, blood pressure monitoring, electrocardiogram and necessary imaging follow-up should be performed before and during treatment to ensure medication safety.

The core principles for scientifically handling the side effects of platinib are early detection, early intervention, and individualized management. During the period of medication, patients should regularly review blood, liver function and electrocardiogram, and pay close attention to their physical changes. If abnormal symptoms occur, they should report to the doctor in time. Mild and moderate side effects can usually be alleviated through symptomatic treatment and lifestyle adjustments; for moderate and severe side effects, dose adjustment, temporary discontinuation of medication, or other auxiliary treatments are required under the guidance of a doctor. At the same time, patients should maintain good living habits, including adequate rest, a reasonable diet, moderate exercise and avoiding infections, to assist in the effectiveness of the drug and reduce the risk of side effects. Through scientific and standardized management, most of the adverse reactions caused by platinib can be effectively controlled, allowing patients to safely and continuously complete targeted therapy and improve the overall treatment effect.

Reference link:https://www.drugs.com